• Patient Stories
  • Understanding MPNs
    • Understanding MPNS
    • What Is Polycythemia Vera?
    • What Is Essential Thrombocythemia?
    • What Is Primary Myelofibrosis?
  • Resources
    • Empowered Patients
    • Dictionary
    • Resources
  • Partners
    • Industry Partners
    • International MPN Organizations
    • Partners
  • News Feed
  • Contact
  • MPN Search

PV Reporter

MPN Information and Research Hub

  • About
    • About Us
    • MPN Cancer Connection
    • Contact Us
  • MPN Specialists
  • Blog
  • Media
    • Podcast
      • 01: Polycythemia Vera Diagnosis, PV Reporter, Day 1, Doomsday or Living with a Plan
      • 02: MPN Chronicles – Interview with Dr. Pemmaraju
      • 03: Learn Benefits of Becoming your own MPN Advocate
      • 04: First Hematologist appointment for PV patient
      • 05: Tips to Living Well with an MPN
      • 06: My Plan to beat Coronavirus Blues
    • Videos
    • Dr. Interviews
      • Dr. Jean Jacques Kiladjian ASH 2018 RuxoPeg Phase 1/2 Trial of the Combo of Ruxolitinib and Pegasys in Myelofibrosis Patients
      • Dr. Michael Grunwald ASH 2018 Risk Assessment and Treatment Myelofibrosis Patients at Community Oncology Practices in the U.S.
      • Dr. J.J. Kiladjian ASH 2018 Headline Research Studies
      • ASH 2017 Interview with Dr. Michael Grunwald
        • ASH 2017 Interview with Dr. Raajit Rampal, part 1
        • ASH 2017 with Dr. Raajit Rampal, part 2
        • ASH 2017 Interview with Dr. Jean Jacques Kiladjian, part 1
        • ASH 2017 Interview with Dr. Jean Jacques Kiladjian, part 2
      • ASH 2016 Interviews
        • ASH 2016 Interview with Dr Kiladjian
        • ASH 2016 Interview with Dr Rampal
      • ASH 2015 Interviews
        • ASH 2015 Interview with Dr John Mascarenhas
        • ASH 2015 Interview with Dr Angela Fleischman
      • ASH 2014 Interviews
        • ASH 2014 Interview with Dr Heinz Gisslinger
        • ASH 2014 interview with Dr Richard Stone
  • Treatment
    • How I Treat MPN’s
    • Jakafi
    • INREBIC
    • Interferon treatment for MPNs
  • Support Group

Clinical Trial Finder

Search Results

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

Study Purpose

This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis. This is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years - 99 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study. 2. Age ≥18 years. 3. Diagnosis of PV according to WHO 2008 or WHO 2016 and high-risk stratification according to European LeukemiaNet (ELN) classification. 4. At least one TE after diagnosis or up to 2 years prior to diagnosis. 5. Patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05548062
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Novartis Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Novartis Pharmaceuticals
Principal Investigator Affiliation Novartis Pharmaceuticals
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Italy
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Polycythemia Vera
Additional Details

All patients are already on treatment with hydroxyurea or ruxolitinib at enrollment as per clinical practice and independently of their participation in this study. In addition, the follow-up visits and the evaluation procedures required in the study protocol correspond to current clinical practice. According to local regulations related to observational studies, assessments such as blood tests are justified by the purpose and rationale of the study (i.e., the identification of possible predictive factors of TEs) and are considered current clinical practice. Data related to other procedures will be collected only if such procedures are performed as per clinical practice but are not required otherwise. Patients in both cohorts will be followed for 3 years after enrollment and will have visits at Months 6, 12, 18, 24, 30 and 36. A time window of ± 1 month is permitted for all visits.

Arms & Interventions

Arms

: Hydroxyurea

Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance.

: Ruxolitinib

Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment.

Interventions

Other: - Hydroxyurea

Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.

Other: - Ruxolitinib

Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Novartis Investigative Site, Alessandria, AL, Italy

Status

Recruiting

Address

Novartis Investigative Site

Alessandria, AL, 15100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Ancona, AN, Italy

Status

Recruiting

Address

Novartis Investigative Site

Ancona, AN, 60126

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Bari, BA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Bari, BA, 70124

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Bologna, BO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Bologna, BO, 40138

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Como, CO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Como, CO, 22100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Cosenza, CS, Italy

Status

Recruiting

Address

Novartis Investigative Site

Cosenza, CS, 87100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Catania, CT, Italy

Status

Recruiting

Address

Novartis Investigative Site

Catania, CT, 95123

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Firenze, FI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Firenze, FI, 50134

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Genova, GE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Genova, GE, 16132

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Lecce, LE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Lecce, LE, 73100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Tricase, LE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Tricase, LE, 73039

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Monza, MB, Italy

Status

Recruiting

Address

Novartis Investigative Site

Monza, MB, 20900

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Milano, MI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Milano, MI, 20122

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Palermo, PA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Palermo, PA, 90127

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Palermo, PA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Palermo, PA, 90146

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Piacenza, PC, Italy

Status

Recruiting

Address

Novartis Investigative Site

Piacenza, PC, 29100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Padova, PD, Italy

Status

Recruiting

Address

Novartis Investigative Site

Padova, PD, 35100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Pisa, PI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Pisa, PI, 56126

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Parma, PR, Italy

Status

Recruiting

Address

Novartis Investigative Site

Parma, PR, 43100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Reggio Calabria, RC, Italy

Status

Recruiting

Address

Novartis Investigative Site

Reggio Calabria, RC, 89124

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Reggio Emilia, RE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Reggio Emilia, RE, 42100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00144

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00161

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00168

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00189

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Pagani, SA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Pagani, SA, 84016

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Orbassano, TO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Orbassano, TO, 10043

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Torino, TO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Torino, TO, 10126

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Terni, TR, Italy

Status

Recruiting

Address

Novartis Investigative Site

Terni, TR, 05100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Varese, VA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Varese, VA, 21100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Vicenza, VI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Vicenza, VI, 36100

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Verona, VR, Italy

Status

Recruiting

Address

Novartis Investigative Site

Verona, VR, 37126

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Viterbo, VT, Italy

Status

Recruiting

Address

Novartis Investigative Site

Viterbo, VT, 01033

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Napoli, Italy

Status

Recruiting

Address

Novartis Investigative Site

Napoli, , 80131

Site Contact

[email protected]

+41613241111

Novartis Investigative Site, Napoli, Italy

Status

Recruiting

Address

Novartis Investigative Site

Napoli, , 80132

Site Contact

[email protected]

+41613241111

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

RSS MPN News

  • Contemporary Approach CALR Positive MPNs
  • 9 Tips to Reduce MPN Fatigue
  • Common Clinical Trial Acronyms and Abbreviations
  • Understanding the Phases of Clinical Trials
  • 4th Angel providing one-on-one support services for MPN Patients

MPN 2019 guidelines

MPN 2019 Guidelines, PV Reporter

Click on the image above for the New MPN Patient Guidelines! Very detailed, provided by NCCN.

Medical Dislaimer

Sign up for Our Newsletter!

Copyright · PV Reporter © 2021 · Site Design by David Wallace
error: